Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Edward Walker is active.

Publication


Featured researches published by Edward Walker.


Bioorganic & Medicinal Chemistry Letters | 2008

Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.

Monika Ermann; Doris Riether; Edward Walker; Innocent Mushi; James Edward Jenkins; Beatriz Noya-Marino; Mark L. Brewer; Malcolm Taylor; Patricia Amouzegh; Stephen Peter East; Brian W. Dymock; Mark J. Gemkow; Andreas Kahrs; Andreas Ebneth; Sabine Löbbe; Kathy O’Shea; Daw-Tsun Shih; David S. Thomson

A high-throughput screening campaign resulted in the discovery of a highly potent dual cannabinoid receptor 1 (CB1) and 2 (CB2) agonist. Following a thorough SAR exploration, a series of selective CB2 full agonists were identified.


Expert Opinion on Therapeutic Patents | 2014

Tropomyosin receptor kinase inhibitors: a patent update 2009 – 2013

Clive Mccarthy; Edward Walker

Introduction: Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. Areas covered: This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets. Additional patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is observed and the chemical matter is particularly noteworthy. Patents pre-dating this period have been reviewed previously. Scifinder and Google were used to find relevant patents and clinical information using Trk or Tropomyosin as the search term. Expert opinion: Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation. Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted molecules have been identified. Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biology of this isoform to be probed. The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.


Bioorganic & Medicinal Chemistry Letters | 2011

1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.

Doris Riether; Lifen Wu; Pier F. Cirillo; Angela Berry; Edward Walker; Monika Ermann; Beatriz Noya-Marino; James Edward Jenkins; Dan Albaugh; Claudia Albrecht; Michael B. Fisher; Mark J. Gemkow; Heather Grbic; Sabine Löbbe; Clemens Möller; Kathy O’Shea; Achim Sauer; Daw-Tsun Shih; David S. Thomson

A high-throughput screening campaign has identified 1,4-diazepane compounds which are potent Cannabinoid receptor 2 agonists with excellent selectivity against the Cannabinoid receptor 1. This class of compounds suffered from low metabolic stability. Following various strategies, compounds with a good stability in liver microsomes and rat PK profile have been identified.


Bioorganic & Medicinal Chemistry Letters | 2011

Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.

Renee M. Zindell; Edward Walker; John Scott; Patricia Amouzegh; Lifen Wu; Monika Ermann; David S. Thomson; Micheal B. Fisher; Cody Lee Fullenwider; Heather Grbic; Paul Kaplita; Brian Linehan; Mita Patel; Monica Patel; Sabine Löbbe; Svenja Block; Claudia Albrecht; Mark J. Gemkow; Daw-Tsun Shih; Doris Riether

A high throughput screening campaign identified aryl 1,4-diazepane compounds as potent and selective cannabinoid receptor 2 agonists as compared to cannabinoid receptor 1. This class of compounds suffered from poor drug-like parameters as well as low microsomal stability and poor solubility. Structure-activity relationships are described with a focus on improving the drug-like parameters resulting in compounds with improved solubility and permeability.


Archive | 2008

Diazepane Compounds Which Modulate The CB2 Receptor

Pier F. Cirillo; Eugene R. Hickey; Doris Riether; Lifen Wu; Renee M. Zindel; Patricia Amouzegh; Monika Ermann; Edward Walker


Archive | 2008

Arylsulfonamide compounds which modulate the cb2 receptor

David S. Thomson; Doris Riether; Renee M. Zindell; Eugene R. Hickey; Monika Ermann; James Edward Jenkins; Innocent Mushi; Malcolm Taylor; Patricia Amouzegh; Edward Walker


Archive | 2011

Substituted naphthyridines and their use as syk kinase inhibitors

Matthias Hoffmann; Georg Dahmann; Dennis Fiegen; Sandra Handschuh; Jasna Klicic; Guenter Linz; Gerhard Schaenzle; Andreas Schnapp; Stephen Peter East; Michael Philip Mazanetz; John Scott; Edward Walker


Archive | 2015

Substituted naphthyridines and their use as medicaments

Matthias Hoffmann; Georg Dahmann; Dennis Fiegen; Sandra Handschuh; Jasna Klicic; Guenter Linz; Gerhard Schaenzle; Andreas Schnapp; Stephen Peter East; Michael Philip Mazanetz; Robert John Scott; Edward Walker


Archive | 2015

Heteroaryl syk inhibitors

Georg Dahmann; Matthias Hoffmann; Jasna Klicic; David James Lamb; Clive Mccarthy; Spencer Napier; Karen Parrish; John Scott; Jennifer L. Swantek Fitzgerald; Edward Walker


Archive | 2016

COMPUESTOS HETEROARILOS Y SU USO COMO MEDICAMENTOS

Georg Dahmann; Matthias Hoffmann; Clive Mcarthy; Jasna Klicic; David James Lamb; Spencer Napier; Karen Parrish; John Scott; Jennifer L. Swantek Fitzgerald; Edward Walker

Collaboration


Dive into the Edward Walker's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John Scott

Cross Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge